1
|
Sengupta S, Biswas M, Gandhi KA, Gupta SK, Gera PB, Gota V, Sonawane A. Preclinical evaluation of engineered L-asparaginase variants to improve the treatment of Acute Lymphoblastic Leukemia. Transl Oncol 2024; 43:101909. [PMID: 38412663 PMCID: PMC10907863 DOI: 10.1016/j.tranon.2024.101909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Revised: 01/13/2024] [Accepted: 02/06/2024] [Indexed: 02/29/2024] Open
Abstract
INTRODUCTION Escherichia coli l-asparaginase (EcA), an integral part of multi-agent chemotherapy protocols of acute lymphoblastic leukemia (ALL), is constrained by safety concerns and the development of anti-asparaginase antibodies. Novel variants with better pharmacological properties are desirable. METHODS Thousands of novel EcA variants were constructed using protein engineering approach. After preliminary screening, two mutants, KHY-17 and KHYW-17 were selected for further development. The variants were characterized for asparaginase activity, glutaminase activity, cytotoxicity and antigenicity in vitro. Immunogenicity, pharmacokinetics, safety and efficacy were tested in vivo. Binding of the variants to pre-existing antibodies in primary and relapsed ALL patients' samples was evaluated. RESULTS Both variants showed similar asparaginase activity but approximately 24-fold reduced glutaminase activity compared to wild-type EcA (WT). Cytotoxicity against Reh cells was significantly higher with the mutants, although not toxic to human PBMCs than WT. The mutants showed approximately 3-fold lower IgG and IgM production compared to WT. Pharmacokinetic study in BALB/c mice showed longer half-life of the mutants (KHY-17- 267.28±9.74; KHYW-17- 167.41±14.4) compared to WT (103.24±18). Single and repeat-doses showed no toxicity up to 2000 IU/kg and 1600 IU/kg respectively. Efficacy in ALL xenograft mouse model showed 80-90 % reduction of leukemic cells with mutants compared to 40 % with WT. Consequently, survival was 90 % in each mutant group compared to 10 % with WT. KHYW-17 showed over 2-fold lower binding to pre-existing anti-asparaginase antibodies from ALL patients treated with l-asparaginase. CONCLUSION EcA variants demonstrated better pharmacological properties compared to WT that makes them good candidates for further development.
Collapse
Affiliation(s)
- Soumika Sengupta
- School of Biotechnology, Campus-11, KIIT Deemed to be University, Bhubaneswar, 751024, Odisha, India
| | - Mainak Biswas
- School of Biotechnology, Campus-11, KIIT Deemed to be University, Bhubaneswar, 751024, Odisha, India
| | - Khushboo A Gandhi
- Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Khargarh, Navi Mumbai, 410210, India; Homi Bhabha National Institute, Training School Complex, Anushaktinagar, Mumbai, 400094, India
| | - Saurabh Kumar Gupta
- Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Khargarh, Navi Mumbai, 410210, India; Homi Bhabha National Institute, Training School Complex, Anushaktinagar, Mumbai, 400094, India
| | - Poonam B Gera
- Department of Pathology, ACTREC, Tata Memorial Centre, Khargarh, Navi Mumbai, 410210, India; Homi Bhabha National Institute, Training School Complex, Anushaktinagar, Mumbai, 400094, India
| | - Vikram Gota
- Department of Clinical Pharmacology, ACTREC, Tata Memorial Centre, Khargarh, Navi Mumbai, 410210, India; Homi Bhabha National Institute, Training School Complex, Anushaktinagar, Mumbai, 400094, India.
| | - Avinash Sonawane
- School of Biotechnology, Campus-11, KIIT Deemed to be University, Bhubaneswar, 751024, Odisha, India; Department of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore (IIT Indore), Khandwa Road, Simrol, Madhya Pradesh, 453552, India.
| |
Collapse
|
7
|
Charbonneau D, Aubé A, Rachel NM, Guerrero V, Delorme K, Breault-Turcot J, Masson JF, Pelletier JN. Development of Escherichia coli Asparaginase II for Immunosensing: A Trade-Off between Receptor Density and Sensing Efficiency. ACS OMEGA 2017; 2:2114-2125. [PMID: 30023654 PMCID: PMC6044767 DOI: 10.1021/acsomega.7b00110] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Accepted: 05/05/2017] [Indexed: 06/08/2023]
Abstract
The clinical success of Escherichia colil-asparaginase II (EcAII) as a front line chemotherapeutic agent for acute lymphoblastic leukemia (ALL) is often compromised because of its silent inactivation by neutralizing antibodies. Timely detection of silent immune response can rely on immobilizing EcAII, to capture and detect anti-EcAII antibodies. Having recently reported the use of a portable surface plasmon resonance (SPR) sensing device to detect anti-EcAII antibodies in undiluted serum from children undergoing therapy for ALL (Aubé et al., ACS Sensors2016, 1 (11), 1358-1365), here we investigate the impact of the quaternary structure and the mode of immobilization of EcAII onto low-fouling SPR sensor chips on the sensitivity and reproducibility of immunosensing. We show that the native tetrameric structure of EcAII, while being essential for activity, is not required for antibody recognition because monomeric EcAII is equally antigenic. By modulating the mode of immobilization, we observed that low-density surface coverage obtained upon covalent immobilization allowed each tetrameric EcAII to bind up to two antibody molecules, whereas high-density surface coverage arising from metal chelation by N- or C-terminal histidine-tag reduced the sensing efficiency to less than one antibody molecule per tetramer. Nonetheless, immobilization of EcAII by metal chelation procured up to 10-fold greater surface coverage, thus resulting in increased SPR sensitivity and allowing reliable detection of lower analyte concentrations. Importantly, only metal chelation achieved highly reproducible immobilization of EcAII, providing the sensing reproducibility that is required for plasmonic sensing in clinical samples. This report sheds light on the impact of multiple factors that need to be considered to optimize the practical applications of plasmonic sensors.
Collapse
Affiliation(s)
- David
M. Charbonneau
- Département
de Chimie and Département de Biochimie, Université
de Montréal, Montréal, Québec H3T 1J4, Canada
- PROTEO
Network, Université Laval, Québec, Québec G1V 0A6, Canada
- Center
for Green Chemistry and Catalysis (CGCC), Montréal, Québec H3A 0B8, Canada
| | - Alexandra Aubé
- Département
de Chimie and Département de Biochimie, Université
de Montréal, Montréal, Québec H3T 1J4, Canada
- Centre
for Self-Assembled Chemical Structures (CSACS), Montréal, Québec H3A 2K6, Canada
| | - Natalie M. Rachel
- Département
de Chimie and Département de Biochimie, Université
de Montréal, Montréal, Québec H3T 1J4, Canada
- PROTEO
Network, Université Laval, Québec, Québec G1V 0A6, Canada
- Center
for Green Chemistry and Catalysis (CGCC), Montréal, Québec H3A 0B8, Canada
| | - Vanessa Guerrero
- Département
de Chimie and Département de Biochimie, Université
de Montréal, Montréal, Québec H3T 1J4, Canada
- PROTEO
Network, Université Laval, Québec, Québec G1V 0A6, Canada
- Center
for Green Chemistry and Catalysis (CGCC), Montréal, Québec H3A 0B8, Canada
| | - Kevin Delorme
- Département
de Chimie and Département de Biochimie, Université
de Montréal, Montréal, Québec H3T 1J4, Canada
- PROTEO
Network, Université Laval, Québec, Québec G1V 0A6, Canada
- Center
for Green Chemistry and Catalysis (CGCC), Montréal, Québec H3A 0B8, Canada
| | - Julien Breault-Turcot
- Département
de Chimie and Département de Biochimie, Université
de Montréal, Montréal, Québec H3T 1J4, Canada
- Centre
for Self-Assembled Chemical Structures (CSACS), Montréal, Québec H3A 2K6, Canada
| | - Jean-François Masson
- Département
de Chimie and Département de Biochimie, Université
de Montréal, Montréal, Québec H3T 1J4, Canada
- Centre
for Self-Assembled Chemical Structures (CSACS), Montréal, Québec H3A 2K6, Canada
| | - Joelle N. Pelletier
- Département
de Chimie and Département de Biochimie, Université
de Montréal, Montréal, Québec H3T 1J4, Canada
- PROTEO
Network, Université Laval, Québec, Québec G1V 0A6, Canada
- Center
for Green Chemistry and Catalysis (CGCC), Montréal, Québec H3A 0B8, Canada
| |
Collapse
|
12
|
Patel N, Krishnan S, Offman MN, Krol M, Moss CX, Leighton C, van Delft FW, Holland M, Liu J, Alexander S, Dempsey C, Ariffin H, Essink M, Eden TO, Watts C, Bates PA, Saha V. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. J Clin Invest 2009; 119:1964-73. [PMID: 19509471 PMCID: PMC2701869 DOI: 10.1172/jci37977] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2008] [Accepted: 04/08/2009] [Indexed: 01/23/2023] Open
Abstract
l-Asparaginase is a key therapeutic agent for treatment of childhood acute lymphoblastic leukemia (ALL). There is wide individual variation in pharmacokinetics, and little is known about its metabolism. The mechanisms of therapeutic failure with l-asparaginase remain speculative. Here, we now report that 2 lysosomal cysteine proteases present in lymphoblasts are able to degrade l-asparaginase. Cathepsin B (CTSB), which is produced constitutively by normal and leukemic cells, degraded asparaginase produced by Escherichia coli (ASNase) and Erwinia chrysanthemi. Asparaginyl endopeptidase (AEP), which is overexpressed predominantly in high-risk subsets of ALL, specifically degraded ASNase. AEP thereby destroys ASNase activity and may also potentiate antigen processing, leading to allergic reactions. Using AEP-mediated cleavage sequences, we modeled the effects of the protease on ASNase and created a number of recombinant ASNase products. The N24 residue on the flexible active loop was identified as the primary AEP cleavage site. Sole modification at this site rendered ASNase resistant to AEP cleavage and suggested a key role for the flexible active loop in determining ASNase activity. We therefore propose what we believe to be a novel mechanism of drug resistance to ASNase. Our results may help to identify alternative therapeutic strategies with the potential of further improving outcome in childhood ALL.
Collapse
Affiliation(s)
- Naina Patel
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Shekhar Krishnan
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Marc N. Offman
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Marcin Krol
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Catherine X. Moss
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Carly Leighton
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Frederik W. van Delft
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Mark Holland
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - JiZhong Liu
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Seema Alexander
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Clare Dempsey
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Hany Ariffin
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Monika Essink
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Tim O.B. Eden
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Colin Watts
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Paul A. Bates
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| | - Vaskar Saha
- Cancer Research UK Children’s Cancer Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, United Kingdom.
Biomolecular Modelling Laboratory, Cancer Research UK London Research Institute, Lincoln’s Inn Fields Laboratories, London, United Kingdom.
Division of Cell Biology and Immunology, School of Life Sciences Research Biocentre, University of Dundee, Dundee, United Kingdom.
Department of Paediatrics, University of Malaya, Kuala Lumpur, Malaysia.
Medac GmbH, Wedel, Germany.
Paediatric and Adolescent Oncology Unit, Christie Hospital, Manchester, United Kingdom
| |
Collapse
|